In combination with anti-PD-L1, MEK inhibition protected tumor infiltrating CD8+ T cells from death driven by chronic TCR signaling; conceivably, this is the same pathway that induces T cell exhaustion. The gene discussed is CD8A; the disease is neoplasm.